Participated · Series B · Jun 2026

xCures builds the Clinical Clarity Engine to aggregate, extract and structure fragmented patient medical records into decision-ready clinical data delivered via a web UI or developer API. The technology was developed over nearly a decade in oncology and is now used across clinical domains and workflows. xCures reports it has processed over 300 million medical records sourced from more than 550,000 healthcare locations, supporting clinical decisions for millions of patients across the U.S. The company links every extracted answer to its source document to enable traceable, evidence-grade decisions. Financially, xCures has raised more than $76 million in total funding following the $46 million Series B. The company plans to use the new capital to accelerate product development, expand its team, and scale adoption across provider, value-based care, diagnostics lab, and consumer health customers.

Led · Series A · Jan 2026

Founded in 2019, TripWorks supplies operators of tours, activities and attractions with a next-generation booking platform infused with artificial intelligence and business intelligence. The software delivers smart pricing recommendations, predictive demand and occupancy analytics, real-time abandoned-cart recovery, automated messaging, generative content tools, OTA channel management, and advanced dashboards. By embedding AI across the reservation journey—from discovery to conversion—the company aims to boost revenue growth and operational efficiency for its customers. Industry data cited by the company show that roughly half of operators are dissatisfied with their current booking systems, and 94% of those already using AI report positive results, underscoring TripWorks’ market opportunity. The platform is currently processing thousands of reservations every day for operators worldwide. With fresh capital, TripWorks plans to enrich its AI-driven pricing and revenue-optimization tools, deepen marketplace integrations, and scale its product and go-to-market teams as it enters new geographies.

Led · Seed · Feb 2025

Hiveclass hosts online courses for K-12 students covering fitness, sports, dance, yoga, nutrition, mindfulness and self-defense through short-form videos paired with quizzes. Educators access a teacher portal to view students and quiz answers, and the platform can be used to earn P.E. credits outside of class. Hiveclass markets primarily to public schools and libraries and says it aligns with national standards from SHAPE America. The company partners with more than 80 educational institutions and has over 13,000 students and teachers on the platform. Financially, Hiveclass has generated more than $2 million in revenue and expects an additional $1 million by next month; it is also exploring licensing agreements as an additional revenue stream. Product roadmaps include enhanced teacher-portal features, product development, and new services for students with special needs. Hiveclass is a New York-based mobile platform that provides kids access to original athlete-led training videos across sports including basketball, soccer, volleyball, tennis, dance and self-defense. The platform also offers supplemental content on resilience, confidence building and other wellness topics. Content can be accessed remotely at home, on the field, or elsewhere, and the product includes a social-emotional learning component that fosters community-building within each sport and activity group. The company is led by co-founders Joe Titus (CEO) and Paul Suhr (CPO). Hiveclass is partnering with schools, libraries and other youth-serving institutions to expand access to top-tier sports training and physical education. It plans to use newly raised capital to accelerate growth and expand operations, team and product.

Led · Series B · Jan 2024

Thentia builds and sells Thentia Cloud, a regulatory-technology platform used by regulators and regulatory agencies worldwide to manage licensing, investigations, enforcement, fitness to practise, quality assurance, scope of practise, continuing education, board management, and data analysis. The company is led by CEO Julian Cardarelli and positions its platform as an alternative to legacy processes, custom-built solutions, and disparate applications. Thentia raised a $38M Series B extension to scale operations and propel accelerated growth. The company plans to invest the proceeds in artificial intelligence and to enhance its ability to meet the needs of its expanding global client base. Thentia emphasized investor support and called its platform “the regulatory platform of the future,” reflecting its strategic focus on technology-led product development. Thentia provides Thentia Cloud, a SaaS platform used by regulatory bodies and government agencies to manage data and licensing with automation and ease of use. Led by CEO Julian Cardarelli, the company serves public-sector customers and emphasizes product and engineering development alongside customer support. Thentia operates globally with teams in the United States, the United Kingdom, and Canada. The platform is trusted by regulatory bodies and government agencies worldwide and supports more than 8 million active licensees. The company intends to use recent funding to invest across product and engineering, and to scale customer-facing services and support teams. These investments are aimed at creating a consistent customer experience across all markets. Thentia offers Thentia Cloud, a proprietary cloud-based licensing platform that supports license registration and renewals, QA, complaints management, governance, finance, document management, analytics, and other regulatory functions. The company partners with licensing agencies across more than 90 occupations and industries coast-to-coast. Thentia grew rapidly in 2021, increasing its employee base by 300% over two quarters, with the majority of new hires based in the U.S. In 2021 it expanded market reach—announcing entry into Quebec and becoming the state-supported software provider for occupational licensing in Oklahoma—and is pursuing broader North American and EMEA expansion. Financially, Thentia secured a $15 million credit facility from Espresso Capital and earlier raised a $10 million Series B in May 2021 led by Spring Mountain Capital with participation from BDC Capital. The company intends to use the financing to fund investments and acquisitions, enhance its product, ramp sales and marketing, and pursue incremental revenue opportunities. Thentia is a Toronto-based GovTech Software-as-a-Service (SaaS) company offering Thentia Cloud, a platform for agencies to manage data and licensing. Led by CEO Julian Cardarelli, the company serves government customers with cloud-based licensing and data-management solutions. In April 2021 Thentia raised $10 million in a Series B financing. The company said it will use the funds to accelerate its go-to-market strategy and expand its position across the U.S. Thentia was founded in Canada and maintains operations in Chicago, IL. The Series B round was led by Spring Mountain Capital with participation from BDC Capital. Thentia is a Toronto-based cloud regulatory software company that provides B2B software-as-a-service solutions to the regulatory industry. Its flagship product, Thentia Cloud, offers a comprehensive collection of regulatory modules that track licensing and registration issuance and renewals, continuing education, public complaints, investigations and enforcement, auditing, data analytics, and governance. The platform serves regulatory bodies, licensees, and registrants across North America and has a major presence in the regulatory and licensure market. Led by CEO Julian Cardarelli, the company will use funds to expand sales and marketing worldwide and further innovate its cloud platform. Thentia closed a Series A equity financing of undisclosed amount with an investment from the Business Development Bank of Canada’s Industrial, Clean and Energy Venture Fund. The financing is intended to support growth and product innovation.

Participated · Series B · Oct 2022

Vergent Bioscience is a clinical-stage biotechnology company developing VGT-309, a tumor-targeted fluorescent imaging agent designed to help surgeons visualize previously undetected or difficult-to-find tumors in real time during open, minimally invasive, and robotic-assisted surgery. VGT-309 is administered via a short infusion hours before surgery and covalently binds cathepsins, proteases overexpressed across many solid tumors; its imaging component is indocyanine green (ICG), compatible with commercially available near-infrared intraoperative imaging systems. Early Phase 1 and 2 trials in Australia demonstrated safety and efficacy in lung cancer and Vergent has initiated a Phase 2 trial at the University of Pennsylvania. The company is first evaluating VGT-309 in lung cancer with plans to expand to colorectal, gastrointestinal, and breast cancers. Vergent is privately held and based in Minneapolis, MN, and has raised a total of $34 million to date. Vergent Bioscience, led by President and CEO John Santini, is developing a tumor-targeted, fluorescent probe that binds to enzymes overexpressed in tumor tissue and activates a brightly fluorescing dye. The probe is intended to provide surgeons with a visual guide to identify and completely remove cancerous tissue and associated metastases. Vergent’s proprietary probe is under development for multiple cancers, including lung, breast, ovarian, colorectal and brain cancers. The company plans to use the newly raised funds to advance its preclinical and clinical development activities. The technology is positioned for intraoperative use to improve tumor visualization during surgery. The company is based in Minneapolis.